Avidity Biosciences — Technical Presentation (August 2024)
25 slides from Avidity Biosciences's technical presentation, Aug 9, 2024
Slide 1: Transforming Duchenne Muscular Dystrophy (DMD): AOC 1044 EXPLORE44 Phase 1/2 Initial Data
1 August 9, 2024 NASDAQ: RNA | aviditybio.com Investor & Analyst Event Series – Volume 10 Transforming Duchenne Muscular Dystrophy (DMD) AOC 1044 EXPLORE44TM Phase 1/2 Initial Data
Slide 2: Forward-looking statements
2 We caution the reader that this presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this presentation are forward-looking statements. Forward-looking statements include, but are not
Slide 3: Our Vision
3 OUR VISION To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics Amy Living with FSHD Nathan, living with DMD, and his father, Brad
Slide 4: Purpose of Update
4 Purpose of Update Present initial data from Phase 1/2 EXPLORE44 Del-zota 5mg/kg at 4-month timepoint • Unsurpassed delivery to muscle • Statistically significant robust exon skipping • Statistically significant dystrophin production • Profound reduction in creatine kinase • Favorable safety and to
Slide 5: Del-zota: Potential New Treatment for People Living with DMD44
5 Del-zota: Potential New Treatment for People Living with DMD44 Unsurpassed Delivery to Muscle • Consistent delivery of PMO of 200 nM in skeletal muscle Significant Exon Skipping • Robust 37% increase in exon skipping • Up to 66% increase in exon skipping Significant Dystrophin Production • Substan
Slide 6: Avidity Management Team
6 Steve Hughes, M.D. Chief Medical Officer Sarah Boyce President & CEO W. Michael Flanagan, Ph.D. Chief Scientific & Technical Officer Michael MacLean Chief Financial & Business Officer Transforming the Treatment of DMD AVIDITY MANAGEMENT TEAM
Slide 7: Transforming the Treatment of DMD44
Transforming the Treatment of DMD44
Slide 8: DMD: Hereditary Disorder Causing Progressive, Debilitating Muscle Damage
8 DMD: Hereditary Disorder Causing Progressive, Debilitating Muscle Damage and Significantly Reduced Life Expectancy • Monogenic, X-linked, recessive condition characterized by progressive muscle damage and weakness • Primarily affects males, loss of ambulation by teenage years • Significantly reduc
Slide 9: EXPLORE44 Phase 1/2 DMD44 Cohorts: Overview & Objectives
9 EXPLORE44 Phase 1/2 DMD44 Cohorts: Overview & Objectives • Measures of muscle function • Patient-reported outcomes (PRO) • Quality of life Key Exploratory ObjectivesKey Information • Pharmacokinetics • Pharmacodynamics • Exon 44 skipping • Dystrophin protein levels Secondary ObjectivesPrimary Obje
Slide 10: Demographics and Baseline Characteristics
10 Demographics and Baseline Characteristics Placebo N=3 mean (SD) Del-Zota 5.0 mg/kg N=9 mean (SD) Age (yrs) 13.7 (2.5) 16.0 (4.7) BMI (kg/m2) 23.1 (5.5) 24.2 (5.6) Age of Symptom Onset (yrs) 3.8 (2.9) 3.6 (2.3) Creatine Kinase, U/L 7,118 (1659) 5,033 (3246) Corticosteroid Use 100% 100%
Slide 11: Del-zota: Favorable Safety and Tolerability in DMD44 Patients
11 Del-zota: Favorable Safety and Tolerability in DMD44 Patients Subjects with ≥ 1 TEAE n (%) Placebo N=7 5.0 mg/kg N=9 10 mg/kg N=9 Any AE 4 (57%) 8 (89%) 4 (44%) Related to study drug 0 2 (22%) 1 (11%) Serious AE (SAE) 0 1 (11%) 0 AE leading to study discontinuation 0 2 (22%) 0 AE leading to death
Slide 12: Expediting Del-zota Registrational Plan
12 Expediting Del-zota Registrational Plan 3: 1 Ra nd om iz at io n AO C 10 44 : P la ce bo A Healthy Volunteer Cohorts B1 B2 5.0 mg/kg 10.0 mg/kg Dose – dose listed is PMO Initiation of next dose level cohort Part A: Healthy Volunteers Part B: Participants with DMD amenable to exon 44 skipping 7.5-
Slide 13: Del-zota: Initial Data from 5mg/kg Cohort
Del-zota: Initial Data from 5mg/kg Cohort
Slide 14: Del-zota: Transforming the Treatment of DMD44
14 Del-zota: Transforming the Treatment of DMD44 Unsurpassed Delivery to Muscle Statistically Significant Robust Exon Skipping Statistically Significant Dystrophin Production Profound Decrease in Creatine Kinase Biomarker • Consistent delivery of PMO of 200 nM in skeletal muscle • Once again, reinfo
Slide 15: Del-zota Produces Near Full-Length Dystrophin
15 Del-zota Produces Near Full-Length Dystrophin Naturally occurring dystrophin Representative dystrophin produced by del-zota Micro-dystrophin produced by gene therapies N H1 R1 R2 R3 H2 R 24 H4 CR N H1 R1 R2 R3 H2 R4 R5 R6 R7 R8 R9 R 10 R 11 R 12 R 13 R 14 R 15 R 16 R 17 R 18 R 19 H3 R 20 R 21 R 2
Slide 16: Del-zota: Unsurpassed Delivery to Muscle in DMD Participants
16 Del-zota: Unsurpassed Delivery to Muscle in DMD Participants Single Dose Q6W X 3 0 50 100 150 200 PM O 44 (n M ) DMD44 HV Del-Zota (5 mg/kg) D D exon44 HV HV DMD44 del-zota (5 mg/kg) PMO44 muscle tissue concentrations were determined utilizing HPLC. Muscle biopsy collected from vastus lateralis (
Slide 17: Del-zota: Increase of 37% in Exon Skipping
17 Del-zota: Increase of 37% in Exon 44 Skipping Statistically significant increase in exon 44 skipping of up to 66% Muscle biopsy collected from biceps brachii at 1 month post last dose (q6W x 3). Mean +/- SEM. N=3 placebo and N=7 del-zota. Exon 44 skipping determined using ddPCR. *p<0.05 by Wilcox
Slide 18: Del-zota: Increase of 25% of Normal in Dystrophin Production
18 Del-zota: Increase of 25% of Normal in Dystrophin Production Significantly restored total dystrophin up to 54% of normal Dystrophin protein determined in biceps brachii muscle biopsy at 1 month post 3rd dose by Western Blot. Data normalized to myosin heavy chain. Mean +/- SEM. N=3 (Placebo), N=7
Slide 19: Del-zota: Creatine Kinase Levels Decrease to Near Normal
19 Del-zota: Creatine Kinase Levels Decrease to Near Normal Creatine kinase reduced by greater than 80% compared to baseline Upper limit of normal (ULN) 0 10 20 30 40 50 60 70 80 90 100 110 120 0 2000 4000 6000 8000 10000 12000 14000 Study Day C re at in e K in as e (U /L ) m ea n (S EM ) PBO (N=3)
Slide 20: Del-zota: First of Multiple AOCs in DMD Franchise
20 Del-zota: First of Multiple AOCs in DMD Franchise Data support expediting advancement of additional exon-skipping candidates Unsurpassed Delivery to Muscle Statistically Significant Robust Exon Skipping Statistically Significant Dystrophin Production Profound Decrease in Creatine Kinase Biomarker
Slide 21: Revolutionizing the Delivery of RNA Therapeutics
Revolutionizing the Delivery of RNA Therapeutics
Slide 22: Avidity is Committed to Partnering with the DMD Community
22 Avidity is Committed to Partnering with the DMD Community to Efficiently Advance Treatment Options • FDA has granted del-zota Orphan Drug, Fast Track and Rare Pediatric Disease designations. EMA has granted del-zota Orphan designation • EXPLORE44 enrollment complete; plan to enroll additional pat
Slide 23: Our Vision
23 OUR VISION To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics Amy Living with FSHD Lee, living with DMD, and his family
Slide 24: Q&A
24 August 9, 2024 NASDAQ: RNA | aviditybio.com Investor & Analyst Event Series – Volume 10 Transforming Duchenne Muscular Dystrophy (DMD) AOC 1044 EXPLORE44TM Phase 1/2 Initial Data Q&A
Slide 25: Transforming Duchenne Muscular Dystrophy (DMD): AOC 1044 EXPLORE44 Phase 1/2 Initial Data
25 August 9, 2024 NASDAQ: RNA | aviditybio.com Investor & Analyst Event Series – Volume 10 Transforming Duchenne Muscular Dystrophy (DMD) AOC 1044 EXPLORE44TM Phase 1/2 Initial Data
Avidity Biosciences — Technical Presentation (August 2024) on 6ix